NEW YORK - A new Covid-19 vaccine is due to be out in September, but health experts and analysts say it is likely to be coolly received even as hospitalisations fromSome public health experts hope that Americans will welcome the new shot as they would a flu jab. But demand for the vaccine has dropped sharply since 2021 when it first became available and more than 240 million people in the US, or 73 per cent of the population, received at least one shot.
They will be fighting declining concern about the virus, as well as fatigue and scepticism about the merits of this vaccine, Dr Ashley Kirzinger, Kaiser Family Foundation director of Survey Methodology, said. In 2022, Pfizer and Moderna’s vaccine sales topped US$56 billion worldwide; analysts project around US$20 billion for 2023.“Take a look at what happened last winter. It was 50 million in the US, and it seems likely to be lower than that, given that there’s less concern about Covid-19 this year than last year,” he said.The Covid-19 public health emergency ended in May, and the government has handed much of the duty of vaccinating America to the private sector. Over 1.
Covid-19 related hospitalisations are up more than 40 per cent off of recent lows hit in June, but are still more than 90 per cent below peak levels hit during the January 2022 Omicron outbreak, according to CDC data.The evidence “Should children really receive this booster?” Dr Schaffner said. “Should the average person with no underlying illness who is a younger adult receive this vaccine, or should this vaccine now be a more targeted vaccine?”
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: STForeignDesk - 🏆 4. / 71 Read more »